Objectives: Impaired cardiac isoform of sarco (endo) plasmic reticulum Ca2+ ATPase
(SERCA2a) activity is a key abnormality in heart failure patients with reduced ejection …

Summary Background Sarcoplasmic/endoplasmic reticulum Ca 2+-ATPase (SERCA2a)
activity is deficient in the failing heart. Correction of this abnormality by gene transfer might …

BACKGROUND: Heart failure (HF) remains a major cause of morbidity and mortality in North
America. With an aging population and an unmet clinical need by current pharmacologic …

Rationale: The Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In
Cardiac Disease (CUPID 1) study was a phase 1/phase 2 first-in-human clinical gene …

BACKGROUND: SERCA2a deficiency is commonly seen in advanced heart failure (HF).
This study is designed to investigate safety and biological effects of enzyme replacement …

Aims Restoration of sarco/endoplasmic reticulum Ca2+ ATPase (SERCA2a) activity through
gene transfer improved cardiac function in experimental and pilot studies in humans with …

Aims Down‐regulation of sarcoplasmic reticulum calcium ATPase (SERCA2a) is a key
molecular abnormality in heart failure (HF), which is not currently addressed by specific …

Background—Adeno-associated virus type 1/sarcoplasmic reticulum Ca2+-ATPase was
assessed in a randomized, double-blind, placebo-controlled, phase 2 study in patients with …

Background—Sarcoplasmic reticulum calcium ATPase 2a (SERCA2a) gene therapy
improves mechanical function in heart failure and is under evaluation in a clinical trial. A …

The cardiac isoform of the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA2a) plays a
major role in controlling excitation/contraction coupling. In both experimental and clinical …